Product
Trastuzumab deruxtecan
Aliases
DS-8201a, DS-8201a, T-DXd, Enhertu, ENHERTU, ENHERTU® (6 other aliases)
Name
T-DXd
Target
HER2+
FDA Approved
Yes
Ema approved
Status
0
36 clinical trials
1 organization
1 drug
7 abstracts
45 indications
1 document
Indication
Breast CancerIndication
Non-small Cell Lung CarcinomaIndication
BladderIndication
Biliary TractIndication
cervicalIndication
Endometrial cancerIndication
OvarianIndication
Pancreatic CancerIndication
Rare TumorsIndication
TumorIndication
StomachIndication
Colorectal CancerIndication
Breast Cancer (HER2-positive)Indication
HER2-low Expressing Breast CancerIndication
AdenocarcinomaIndication
Stomach CancerIndication
Esophageal CancerIndication
Advanced Solid Tumors With HER2 MutationIndication
HepatobiliaryIndication
Advanced Solid TumorsIndication
HER2-low Breast CancerIndication
Advanced CancerIndication
HER2-mutant NSCLCIndication
Gastroesophageal Junction AdenocarcinomaIndication
Breast NeoplasmsIndication
Chemotherapy-induced AlopeciaIndication
Stomach NeoplasmIndication
HER2-positive Early Breast CancerIndication
Lung CancerIndication
Brain CancerIndication
GlioblastomaIndication
Metastatic CancerIndication
Leptomeningeal MetastasisIndication
Gastroesophageal CancerIndication
Esophageal adenocarcinomaIndication
Esophageal cancerIndication
HER2 Protein OverexpressionIndication
Gastroesophageal Junction CancerIndication
Gastric AdenocarcinomaIndication
Brain MetastasesIndication
Breast Cancer Stage IVDrug
EnhertuIndication
NSCLCIndication
Gastric CancerClinical trial
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)Status: Active (not recruiting), Estimated PCD: 2023-08-16
Clinical trial
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)Status: Active (not recruiting), Estimated PCD: 2023-06-08
Clinical trial
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd)Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-low Europe)Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).Status: Active (not recruiting), Estimated PCD: 2024-09-04
Clinical trial
A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)Status: Active (not recruiting), Estimated PCD: 2022-12-23
Clinical trial
A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)Status: Completed, Estimated PCD: 2021-11-08
Clinical trial
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)Status: Recruiting, Estimated PCD: 2026-07-30
Clinical trial
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab DeruxtecanStatus: Not yet recruiting, Estimated PCD: 2025-04-04
Clinical trial
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor HistologyStatus: Active (not recruiting), Estimated PCD: 2023-01-25
Clinical trial
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Patients With Selected HER2-overexpressing Tumors (DESTINY PanTumor03)Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneStatus: Active (not recruiting), Estimated PCD: 2021-05-21
Clinical trial
A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)Status: Active (not recruiting), Estimated PCD: 2023-09-23
Clinical trial
A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)Status: Recruiting, Estimated PCD: 2026-12-01
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Maria Sklodowska-Curie National Research Institute and Oncology Centre (MSCI), Warsaw, Poland, Hospital Clínico San Carlos and IdISSC, Madrid, Spain,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Org: Daiichi Sankyo Co, Ltd., Daiichi Sankyo Inc.,
Clinical trial
A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-11-14
Clinical trial
Assessing the Impact of Scalp Cooling in With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Prospective Phase Ib Study of Anlotinib With Trastuzumab Deruxtecan for HER2-Low Unresectable and/or Metastatic Breast Cancer (ALTER-BC-Ib-01)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Ph 1/2 Study of Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer(VIKTORY-2)Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNEStatus: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Trastuzumab-deruxtecan Versus Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2 Trial to Assess Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases.Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)Status: Recruiting, Estimated PCD: 2027-09-22
Clinical trial
A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 PositiveStatus: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal JunctionStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Basket Study for Oligo-metastatic Breast Cancer Part 1: Trastuzumab-deruxtecan for HER2-positive Oligo-metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in BrazilStatus: Active (not recruiting), Estimated PCD: 2024-05-27
Clinical trial
A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMENStatus: Not yet recruiting, Estimated PCD: 2026-04-30
Clinical trial
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)Status: Recruiting, Estimated PCD: 2027-02-22
Clinical trial
Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal CarcinomatosisStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesStatus: Completed, Estimated PCD: 2023-05-01
Document
DailyMed Label: EnhertuOrganization
Daiichi Sankyo Inc.